UNSPSC 51401542: Oxazepam

This classification denotes a benzodiazepine with the molecular formula C15H11ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6GOW6DWN2A, chemically known as 1,3-dihydro-7-chloro-3-hydroxy-5-phenyl-3h-1,4-benzodiazepin-2-one but generally known as oxazepam, which bears US NIH Compound Identifier 4616. European Medicines Agency schedules Oxazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09506MIG.

UNSPSC 51401542 Oxazepam, a Commodity code, does not map cleanly to recent state and local procurement activity. The one recent opportunity posted under this code—Seminole County, Florida's IFB60459723LAS—solicits naloxone and drug deactivation systems for community health initiatives, not oxazepam or other benzodiazepine pharmaceutical products. The mismatch suggests either a tagging error in the source data or a shift in how Seminole County categorizes emergency-response medical supplies. State and local health departments, counties, and public health authorities that do procure oxazepam as a pharmaceutical typically source it through group purchasing organizations, state health procurement offices, or correctional health programs rather than as a standalone IFB. The code shows minimal recent activity under its actual pharmaceutical scope.

The single opportunity on record—Seminole County's naloxone and drug deactivation system procurement posted on June 30, 2026, with a response deadline of July 26, 2023—calls for 1,900 units of naloxone and 800 safe drug deactivation systems on an annual basis with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The IFB requires electronic bid submission, includes shipping and delivery costs in the proposal, mandates E-Verify compliance and drug-free workplace certification, and carries a two-year initial term with a one-year renewal option. The procurement is potentially FEMA-funded and includes a three-month probationary termination clause. No explicit set-aside designations are noted. Given the scope mismatch and absence of other recent oxazepam-specific solicitations, this code does not present a clear pursuit opportunity for firms focused on pharmaceutical supply to state and local government.